COCH Stock Forecast: Envoy Medical, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Envoy Medical, Inc. hold a median 12-month price target of $18 — +168.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 57 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Envoy Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (84): Analysts have, on balance, been raising their forecasts.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
COCH stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on COCH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +168.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $18 |
| 27 Oct 2026 | Lake Street | Maintains | Buy | $2.50 → $25 |
| 6 Oct 2026 | Lake Street | Initiates | Buy | $2.50 |
| 21 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $2.50 → $2.00 |
| 27 July 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | $2.00 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $2.50 |
| 31 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | $2.50 |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 14 Oct 2024 | Brookline Capital | Initiates | Buy | — |
| 3 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 24 June 2024 | Ascendiant Capital | Initiates | Buy | — |
| 3 Apr 2024 | Lake Street | Maintains | Buy | — |
| 21 Dec 2023 | Northland Capital Markets | Initiates | Outperform | — |
| 28 Nov 2023 | Lake Street | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for COCH.
This page is one stock. Monday covers all of them.
COCH appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
COCH vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Envoy Medical, Inc. returned −3.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
COCH analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 224.6×
- Price / book
- 188.7×
- EV / EBITDA
- —
Cheaper than 2% of US stocks
Cheaper than 1% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −108.4%
- Dividend yield
- —
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Envoy Medical, Inc. has a market value of $51.9M and an enterprise value of $38.1M.
Revenue in the twelve months to 30 June 2026: $207K. The latest quarter shrank 34.6% year on year.
Net income over the same four quarters: −$23.4M, a −11304.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$21.7M.
Envoy Medical, Inc. spent $1K on dividends in the twelve months to 30 June 2026.
Envoy Medical, Inc. employs 43 people — $5K of revenue per employee.
Data provided by Twelve Data
COCH and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at COCH’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Envoy Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about COCH
What is the COCH stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Envoy Medical, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is COCH stock a buy right now?
Of the 3 analysts covering Envoy Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Envoy Medical, Inc. 57 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank COCH?
As at 21 Nov 2026, Envoy Medical, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (84 of 100).
Will COCH stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +168.7% from the last close, and Ticker Nerd's factor model ranks Envoy Medical, Inc. 57 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the COCH stock forecast for 2030?
No analyst covering Envoy Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COCH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $25 over the next 12 months.
How has COCH stock performed over the past year?
Envoy Medical, Inc. returned -3.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Envoy Medical, Inc. do?
Envoy Medical Inc Class A Common Stock represents ownership in Envoy Medical, a hearing health company focused on medical technologies for people with hearing loss. The company develops and markets fully implanted hearing solutions, with its current product portfolio centered on the Esteem FI-AMEI, a fully implanted active middle ear implant, and related replacement components.
About Envoy Medical, Inc.
Envoy Medical Inc Class A Common Stock represents ownership in Envoy Medical, a hearing health company focused on medical technologies for people with hearing loss. The company develops and markets fully implanted hearing solutions, with its current product portfolio centered on the Esteem FI-AMEI, a fully implanted active middle ear implant, and related replacement components. Envoy Medical also has an investigational cochlear implant program under development, reflecting its broader role in the hearing device market. Based in White Bear Lake, Minnesota, the company operates in the healthcare and medical devices space and serves patients and providers seeking alternatives to traditional hearing aids and other hearing technologies. Its business is concentrated in the hearing segment, where it aims to improve usability, access, and quality of life through implantable solutions.
CEO Mr. Brent T. Lucas Esq. · 43 employees · United States · https://www.envoymedical.com